#PALB2
Longitudinal Pancreatic Imaging Findings in BRCA1, BRCA2, ATM, and PALB2 Heterozygotes Undergoing #PancreaticCancer Surveillance: A Prospective PRECEDE Consortium Study. ascopubs.org/doi/10.1200/...
Longitudinal Pancreatic Imaging Findings in BRCA1, BRCA2, ATM, and PALB2 Heterozygotes Undergoing Pancreatic Cancer Surveillance: A Prospective PRECEDE Consortium Study | JCO Precision Oncology
PurposeImaging surveillance for pancreatic cancer (PC) is recommended for select high-risk individuals (HRIs) with a goal of downstaging PC diagnosis and improving long-term survival. A common subgrou...
ascopubs.org
November 5, 2026 at 10:34 AM
ASCO member and JCO PO co-author Dr. Bryson Katona of @pennmedicine.bsky.social explains the data from “Pancreatic Imaging Findings in BRCA1/BRCA2/ATM/PALB2 Carriers”.

Learn more: https://bit.ly/4zUzhcm
November 3, 2026 at 10:30 PM
‼️ #CGAIGC26 simultaneous publication by Katona, et al.

Longitudinal Pancreatic Imaging Findings in BRCA1, BRCA2, ATM, and PALB2 Heterozygotes Undergoing Pancreatic Cancer Surveillance: A Prospective PRECEDE Consortium Study

Read the full publication. https://bit.ly/4z8jk2z
November 3, 2026 at 10:10 PM
Ni les BRCA ni d'autres oncogène comme PALB2 ou TP53.. ( il en ont cherché 11 en tout).
Et pourtant elle a fait deux cancers du sein, un a 35 ans qui n'a jamais métastasé et un autre sur l'autre sein a 45 ans qui a métastasé 2 ans après l'opération.
October 13, 2026 at 9:20 PM
Beyond BRCA: What really increases your breast cancer risk

The short answer: BRCA1 and BRCA2 are not the only genes that raise breast cancer risk. Research has identified several other inherited gene changes, including PALB2, ATM, CHEK2, BARD1, and RAD51D, that increase risk by varying amounts…
Beyond BRCA: What really increases your breast cancer risk
The short answer: BRCA1 and BRCA2 are not the only genes that raise breast cancer risk. Research has identified several other inherited gene changes, including PALB2, ATM, CHEK2, BARD1, and RAD51D, that increase risk by varying amounts [1]. Family history matters even when BRCA testing is negative. A 2026 study found that women who test negative for BRCA mutations still had a 25 percent lifetime risk if they had a family history of cancer [2]. And most breast cancers, about 80 percent, occur in women with no specific risk factors other than being female and getting older [5].
trenderhq.com
October 9, 2026 at 8:25 AM
13. Regulation and #pharmacological targeting of #RAD51 in cancer - Grundy et al. doi.org/10.1093/narc.... Review article on RAD51, the central recombinase regulated by BRCA2, PALB2 and RAD51 paralogs, linking HR control to #cancerprevention and #therapeuticresistance. 14/18
Regulation and pharmacological targeting of RAD51 in cancer
Abstract. Regulation of homologous recombination (HR) is central for cancer prevention. However, too little HR can increase cancer incidence, whereas too m
doi.org
October 7, 2026 at 1:44 AM
10. #Homologous recombination, cancer and the ‘RAD51 paradox’ - Matos-Rodrigues et al.
doi.org/10.1093/narc.... BRCA1, BRCA2, PALB2 and RAD51-associated factors placed within HR, replication-fork maintenance, cancer susceptibility, and the consequences of dysregulated recombination. 11/18
Homologous recombination, cancer and the ‘RAD51 paradox’
Abstract. Genetic instability is a hallmark of cancer cells. Homologous recombination (HR) plays key roles in genome stability and variability due to its r
doi.org
October 7, 2026 at 1:44 AM
Thirteen were confirmed as true positives, eight of which were classified as (likely) pathogenic, including small duplications/deletions and mobile element insertions affecting well-established cancer predisposition genes such as MSH6, BARD1, APC, BRCA2, PALB2, and ATM.
October 6, 2026 at 12:52 PM
For breast cancer awareness month:https://msjournalist.substack.com/p/i-learned-i-had-a-lesser-known-palb2?r=l3yn&utm_medium=ios
I Learned I Had a Lesser-known Palb2 Mutation and Shared It On The Today Show
A mutation that leaves you at risk for breast, ovarian and pancreatic cancer
msjournalist.substack.com
October 1, 2026 at 2:00 PM
4/5

Real impact: an MLH1 variant (c.117-6T>A) triggered a cryptic splice site & #exon skipping — reclassified VUS → likely pathogenic, matching the patient's Lynch syndrome tumor. A PALB2 variant at a canonical splice site spliced normally despite looking risky on paper.

#HereditaryCancer #VUS
August 26, 2026 at 3:33 PM
We present a site‑saturation functional screens of missense variants in the high-risk breast cancer susceptibility gene PALB2. Damaging missense variants confer a high risk of breast cancer! Thanks to all co-authors and to KWF for financially supporting our work!

www.nature.com/articles/s41...
Site-saturation functional screens identify PALB2 missense variants associated with increased breast cancer risk - Nature Communications
The impact of variants of uncertain significance (VUS) on protein function and cancer risk remain unclear. Here, the authors focus on the functional impact of VUS of the PALB2 gene and identify defect...
www.nature.com
January 28, 2026 at 10:18 AM
Riesgo absoluto estimado de cáncer de mama asociado a variantes patogénicas
Se puede observar un mayor riesgo en los genes de alta penetrancia (BRCA1, BRCA2 y PALB2) respecto a los de penetrancia moderada (CHEK2, BARD1, ATM, RAD51C y RAD51D) https://buff.ly/3WcHmb8
January 10, 2025 at 9:54 AM
The international trial showed a 37% reduction in cancer growth risk, and even greater benefits for those with BRCA1 or BRCA2 mutations. While side effects were more common, the results support more exhaustive genetic testing and targeted treatment for those most at risk.
Prostate Cancer Patients Offered Fresh Hope by Promising New Drug Combination
New hope for advanced prostate cancer patients, with promising new drug combo that targets genes, such as BRCA1, BRCA2, CHEK2, and PALB2.
www.goodnewsnetwork.org
November 12, 2025 at 12:45 PM
Researchers found that adding niraparib, a targeted therapy, to standard hormone treatment significantly delayed cancer progression in patients with specific genetic mutations.
www.goodnewsnetwork.org/prostate-can...
Prostate Cancer Patients Offered Fresh Hope by Promising New Drug Combination
New hope for advanced prostate cancer patients, with promising new drug combo that targets genes, such as BRCA1, BRCA2, CHEK2, and PALB2.
www.goodnewsnetwork.org
November 12, 2025 at 12:43 PM
These findings, which were published today in www.jci.org/articles/vie... are now being shared internationally, and will enable doctors to provide more informed treatment options to their patients.
JCI - Precision screening facilitates clinical classification of BRCA2-PALB2 binding variants with benign and pathogenic functional effects
www.jci.org
June 19, 2025 at 11:00 AM
To put this in perspective, the bare cost of the 3-gene panel used in this study (BRCA1, BRCA2, PALB2) is around AUD$400 (~£200), plus the costs of the pre- and post- consultation by a doctor or genetic counsellor.
August 8, 2026 at 7:14 AM
If early genetic testing is offered to ALL #BreastCancer patients, the rate of high penetrance genes such as BRCA1/2 is not high- 3.6% (~1 in every 28 women) but significantly influences their choice of surgical procedure.

So, what price women's health? 👀

www.sciencedirect.com/science/arti...
The impact of expanded access to germline high penetrance genetic testing for women with a new diagnosis of invasive breast cancer or high-grade DCIS
Approximately 3% of patients with breast cancer have an inherited pathogenic variant in high-penetrance genes such as BRCA1, BRCA2 or PALB2. Knowledge…
www.sciencedirect.com
August 8, 2026 at 7:03 AM
Strikingly, DNA repair-deficient clones (with BRCA2, PALB2, or RAD51B alterations) contracted under therapy, replaced by repair-proficient resistant clones. This suggests tumor heterogeneity limits response even when some clones are sensitive.
January 29, 2026 at 4:22 PM
💭@neerajagarwal.bsky.social shares insights on pairing targeted treatments.

In mCRPC, BRCA1/2-altered tumors show maximum benefit from PARPi monotherapy. But combo therapy (PARPi + ARPI) may extend benefit to CDK12, PALB2, ATM, though trials weren’t powered for subset analysis

#ESMO25 #MedSky
October 20, 2025 at 7:26 AM
🎀 Monika Grzesiak, Child Health Governance Manager at King’s, discovered she was a carrier for the gene mutation #PALB2, and was at high risk of developing #BreastCancer.

Read more about what she did next ➡️ tinyurl.com/2ejnn8ak 

#TeamKings #BreastCancerAwarenessMonth
October 7, 2025 at 10:04 AM
This is amazing, thank you for sharing. So much hope for the future. 💜 Signed, someone who got rid of their boobs and ovaries because of a mutation in a related gene (PALB2). And lost their father 3 weeks ago to prostate cancer most likely from the same allele.
February 6, 2024 at 3:57 PM